The original second largest chain pharmacy is delisted;

This week, the new crown epidemic is repeated in many places.

Since June 26, Anhui has reported a total of 105 confirmed cases and 467 cases of non -symptoms; several cases of confirmed cases have appeared in Nanjing and Xuzhou, Jiangsu. It is worth mentioning that the seventh batch of national pharmaceutical collection locations have been changed to Nanjing. Whether the epidemic will affect the collection of collection, there is no clear notice.

At the market level, the changes in large domestic and foreign companies and the adjustment of departmental adjustment. Liu Yan, vice president of Baiji Shenzhou and the head of marketing in Greater China, left to join the Pan -raising son; Nuohua's layoffs were 8,000, reaching 7%of the total number of global employees. Most of them were medical representatives and administrative employees.

In terms of new drugs, Murisha's new crown oral medicine Mnupel submits a listing application in China; the new crown mRNA vaccine of Emmy vaccine starts the third phase of the clinical clinical, and plans to enter the group of 1,100 people; Nili Single was approved to be listed, becoming the first domestic double resistance to listing.

The Jianzhi Bureau organizes more hot information as follows:

Heavy policy

1. The fifth round of national medical insurance catalog adjustment work starts

On June 29, the State Medical Insurance Bureau officially announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Adjustment Work Plan" and related documents. The negotiation work started on July 1, the results were announced in November, and the settlement was implemented on January 1, 2022.

It is worth noting that when the State Medical Insurance Administration requires companies to indicate the sales amount in the Chinese market in the first half of this year, and compared with drugs in the same field in the directory, their own products and their own products Essence

2. The Yangtze River Delta Union collection official announcement results

On June 30, Shanghai Sunshine Pharmaceutical Procurement Network announced the results of centralized procurement in the "Yangtze River Delta" alliance regional drug in Shanghai, Zhejiang and Anhui. The collection was opened in Shanghai in February this year and announced on March 17th. However, it was not until 3 months that the final result was announced, and the specific execution date will be notified separately.

This collection involves 47 drugs including amoxicillin particles and sodium chloride injections of Mossicate hydrochloride, all of which are previously used for the national collection of varieties, including Qilu Pharmaceuticals, Hengrui Pharmaceutical, and Caren Pharmaceutical. On the issue of decline, Kelly Pharmaceutical said on May 31st on investors' questions that the average decline in the three provinces of the alliance was about 26%.

3. State Health and Health Commission and other 8 departments to start the reform of the Outstanding Hospital

On June 29, 8 departments such as the Ministry of Retirement Military Affairs, the National Health and Health Commission, and the State Medical Insurance Bureau jointly issued the "Opinions on Promoting the Reform and Development of Outstanding Hospital", which required a comprehensive launch of the reform of the preferential treatment hospital to satisfy the support objects of the disabled retired soldiers Medical needs.

The "Opinions" proposes to integrate the excellent hospital into the medical and health system and enjoy the relevant policies of government office hospitals. In addition, in terms of doctors' salary and benefits, we must incorporate the Yinfu Hospital into the scope of reform of the salary system of the public hospital and dynamically adjust the salary level.

Industry affairs

1. Entry staff requires to check monkey acne

On July 2nd, the National Health and Health Commission issued the "Guide to Monkey Acne Prevention and Control Technology (2022 Edition)" to introduce issues such as the current global epidemic overview, prevention, diagnosis, and disease control.

At present, my country does not report monkey acne cases. The "Guide" is particularly required that local governments should take the initiative to conduct monkey acne virus investigations, especially those who report monkey acne epidemic in the world within 21 days before entering the country. Returned personnel in the epidemic area should pay attention to self -health monitoring. When symptoms such as rash occur, they should take the initiative to seek medical treatment and inform the doctor of the doctor's epidemic area.

In addition, the "Guide" said that there is no anti -anti -acne virus drug in China, and the treatment is mainly to support the treatment and secondary bacterial infection.

2. Tongji Hall is about to delist sooner

On July 1, Tongji Hall issued an announcement saying that the period of delisting and finishing has ended and will be terminated and delisted on July 7. As of April 30 this year, Tongji Tang did not disclose the recent annual report within the statutory period, which was in line with the termination of shares stipulated in Article 9.3.11 of the Shanghai Stock Exchange Stock Listing Rules.

Tongji Hall was established in 2000. Its main chain pharmacy has exceeded 12 billion yuan in annual sales. At the end of 2005, there were 3,425 chain pharmacies in Tongji Hall, ranking second in the country's chain pharmacy. In March 2007, Tongji Hall landed on the New York Stock Exchange. It was the first Chinese medicine company listed in the United States in China.

3. Beijing Jinzhun Medical Test 4 people were arrested

On June 28, according to the official Weibo "Beijing Procuratorate" on the official Weibo of the Beijing Municipal People's Procuratorate, 4 criminal suspects such as Wang Moumou and Xia Moumou, such as Wang Moumou and Xia Moumou, were suspected of obstructing the prevention and treatment of infectious diseases. Approved by the People's Procuratorate of Haidian District, Beijing.

Earlier, during the launch of nucleic acid testing, Beijing Golden League Medical Testing was detected in violation of regulations to test the accuracy of the test results and caused further spread of the epidemic. At present, Beijing Golden League Medical Test has been revoked by the Beijing Market Supervision Department in accordance with the law and included in the list of serious violations of the law.

4. JD health enters pet health

On June 29, JD Health issued an announcement that the company plans to acquire JD.com's pet health -related assets for 355.4 billion US dollars (about 2.3 billion yuan), mainly including pet prescription medicine/prescription grains, pet nutrition products, pet deworming, etc. Product sales and other businesses of category.

This is not the first time JD health has laid out pet -related business. In October 2021, Jingdong Health Pet Hospital officially launched, mainly providing customers with pet online consultation, graphic and video consultation services. New drug inventory

1. The first domestic dual anti -drug was approved to be listed

On June 29, the State Drug Administration issued an announcement saying that the PD-1/CTLA-4 double-specific antibody Kadinilicabette of Kangfang Bio has attached to the independent development of Kangfang Bio has attached to the listing Copy or metastatic cervical cancer patients in the treatment of chemotherapy.

Kadinilicab is the first domestic double resistance to the listing, and it is also the world's first PD-1-based dual-anti-drug-based dual-anti-drug. In addition, it is worth mentioning that the approval time of Kadinilicab has been approved as early as June 30 this year, which means that this product is eligible to apply for the adjustment of the medical insurance directory this year.

2. Lilly Alzheimer's Diseases is approved in China

On June 27, the website of the State Drug Administration's official pharmaceutical review center showed that Donanemab, the new drug of Alzheimer (AD) of Lilly Pharmaceutical, was approved in the country. This is a drug based on the principle of β amyloid -like protein plaques. It has previously obtained the FDA awarding breakthrough therapy.

Earlier, Bo Jian's AD drug Aducanumab was approved in the United States. However, in January this year, the US Federal Medical Insurance and Medical Subsidies Center announced that it restricts this drug reimbursement.

3. Merck's new crown oral medication is declared and listed in China

Recently, Tian Anna, the president of Merck Chinese, said in an interview that she had submitted a listing application for the National Drug Administration for a listing of new crown oral medicine Mnupel.

Phaxlovid Phaxlovid was approved for listing in March this year. Mnipi is another mainstream new crown oral medication. It has obtained listing licenses or urgently authorization authorizations in more than 20 countries or regions around the world, including the United States and Australia.

4. The first 3D printing drug is approved in China

On July 1st, Nanjing Sanxi announced that the company's first 3D printed drug product T19 has been approved by the drug clinical trial of the State Drug Administration. This product is registered in China in China in accordance with type 2.2 -improved new drugs. It is the first domestic 3D printed drug product known to enter clinical.

T19 is designed for the day and night rhythm of rheumatoid arthritis symptoms according to the principle of treatment. In 2021, T19 has been declared clinical in the United States.

Writing | Guyue

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

### 3D printing medicine#

- END -